Skip to content
Medical Health Aged Care

WALLY LEWIS WELCOMES GOVERNMENT PLEDGE TO FUND CTE SUPPORT

Dementia Australia 2 mins read

Wally Lewis AM, Dementia Australia and Connecters Australia Ambassador, today welcomed the comments from the Hon Anika Wells MP, Minister for Aged Care and Minister for Sport, in response to calls for $18M federal government funding for support services, education and awareness raising about concussion and chronic traumatic encephalopathy (CTE).

“While we are yet to see the details, knowing the Minister has confirmed there will be something in the federal budget to address our calls is fantastic news,” Mr Lewis said.

“On behalf of the Concussion and CTE Coalition and all people impacted by chronic traumatic encephalopathy I say thank you.”

“We look forward to finding out more details in the coming weeks.”

The news follows a campaign led by the Concussion and CTE Coalition with Mr Lewis, who is living with probable CTE. Mr Lewis led a 20 strong delegation to parliament in February and addressed the National Press Club of Australia (NPC) yesterday where he shared his experience of living with probable CTE and his hopes for the future.

The Concussion and CTE Coalition’s Joint Pre-Budget Submission calls for $18 million over three years to fund a national pilot program of support services for people impacted by CTE, and a national awareness and education program in schools to protect the brains of Australian children.
CTE is the only preventable form of dementia, and some estimates suggest thousands of people are impacted. CTE affects brain function over time and can result in changes in mood, personality, behaviour, and cognitive function. 

As Mr Lewis said in his speech, “We only get one brain.” 

Read Wally Lewis’ National Press Club address

The Concussion and CTE Coalition includes Dementia Australia, Brain Foundation, ConneCTErs Australia, Associate Professor Fatima Nasrallah of the Queensland Brain Institute at The University of Queensland and Dr Rowena Mobbs of Mater Hospital Sydney, who are working together to promote awareness and understanding of CTE and its impact on individuals, families and communities.

For more information: Concussion and CTE Coalition’s Pre-Budget Submission and Joint Position Statement.

For support and information please contact the National Dementia Helpline 1800 100 500, dementia.org.au, the Brain Foundation brainfoundation.org.au, or Connecters Australia connecters.org.au

Media contacts:  
Gabrielle Prabhu 0403 177 754 | gabrielle.prabhu@dementia.org.au 

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Media

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.